Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SHANGHAI PECHEM
00338
5
KUNLUN ENERGY
00135
| (Q6)Sep 30, 2025 | (FY)Mar 31, 2025 | (Q6)Sep 30, 2024 | (FY)Mar 31, 2024 | (Q6)Sep 30, 2023 | (FY)Mar 31, 2023 | (Q6)Sep 30, 2022 | (FY)Mar 31, 2022 | (Q6)Sep 30, 2021 | (FY)Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | -23,663.85%-194.87M | -84.72%2.64M | --827K | 288.18%17.27M | ---- | -80.90%4.45M | ---- | 87.55%23.3M | ---- | -60.93%12.42M |
| Profit adjustment | ||||||||||
| Impairment and provisions: | ---- | --1.3M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Other impairments and provisions | ---- | --1.3M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Revaluation surplus: | ---- | -54.34%200K | ---- | 2,185.71%438K | ---- | -425.00%-21K | ---- | 95.70%-4K | ---- | -130.49%-93K |
| -Other fair value changes | ---- | -54.34%200K | ---- | 2,185.71%438K | ---- | -425.00%-21K | ---- | 95.70%-4K | ---- | -130.49%-93K |
| Depreciation and amortization: | ---- | -5.20%5.71M | ---- | 6.94%6.02M | ---- | -7.08%5.63M | ---- | 15.80%6.06M | ---- | 52.64%5.23M |
| Financial expense | ---- | -41.77%230K | ---- | 55.51%395K | ---- | -2.31%254K | ---- | -46.72%260K | ---- | 236.55%488K |
| Operating profit before the change of operating capital | -23,663.85%-194.87M | -58.22%10.08M | --827K | 133.93%24.13M | ---- | -65.17%10.32M | ---- | 64.06%29.61M | ---- | -49.40%18.05M |
| Change of operating capital | ||||||||||
| Inventory (increase) decrease | ---- | -39.28%8.5M | ---- | -62.14%14M | ---- | 66.28%36.97M | ---- | 144.45%22.23M | ---- | -296.11%-50.01M |
| Accounts receivable (increase)decrease | ---- | 174.59%725K | ---- | 22.55%-972K | ---- | -159.56%-1.26M | ---- | 255.96%2.11M | ---- | -455.53%-1.35M |
| Accounts payable increase (decrease) | ---- | 146.55%2M | ---- | 2,036.84%812K | ---- | 100.85%38K | ---- | -213.24%-4.46M | ---- | 111.51%3.93M |
| prepayments (increase)decrease | ---- | -7.35%2.23M | ---- | 16,153.33%2.41M | ---- | -100.88%-15K | ---- | 131.17%1.7M | ---- | -1,577.72%-5.44M |
| Cash from business operations | -23,663.85%-194.87M | -41.70%23.54M | --827K | -12.32%40.37M | ---- | -10.04%46.05M | ---- | 247.02%51.19M | ---- | -235.90%-34.82M |
| Other taxs | ---- | -251.46%-5.34M | ---- | 168.22%3.53M | ---- | -2,029.10%-5.17M | ---- | 106.32%268K | ---- | 35.07%-4.24M |
| Special items of business | ---- | ---- | ---- | ---- | -22.32%37.98M | ---- | 670.85%48.89M | ---- | 166.73%6.34M | ---- |
| Adjustment items of business operations | 43,568.82%195.18M | ---- | ---449K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net cash from operations | -20.11%302K | -58.55%18.2M | -99.00%378K | 7.39%43.9M | -22.32%37.98M | -20.56%40.88M | 670.85%48.89M | 231.75%51.46M | 166.73%6.34M | -304.56%-39.06M |
| Cash flow from investment activities | ||||||||||
| Purchase of fixed assets | 34.64%-283K | 92.65%-727K | ---433K | -958.89%-9.89M | ---- | -37.96%-934K | ---- | -14.36%-677K | ---- | 57.56%-592K |
| Purchase of intangible assets | ---6.31M | ---13.34M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash on investment | ---35.03M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Other items in the investment business | ---- | ---- | ---- | ---- | -988,700.00%-9.89M | ---- | 99.70%-1K | ---- | 36.68%-328K | ---- |
| Net cash from investment operations | -9,513.86%-41.63M | -42.25%-14.07M | 95.62%-433K | -958.89%-9.89M | -988,700.00%-9.89M | -37.96%-934K | 99.70%-1K | -14.36%-677K | 36.68%-328K | 61.93%-592K |
| Net cash before financing | -75,038.18%-41.33M | -87.87%4.13M | -100.20%-55K | -14.86%34.01M | -42.54%28.09M | -21.34%39.94M | 712.87%48.89M | 228.08%50.78M | 160.01%6.01M | -326.07%-39.65M |
| Cash flow from financing activities | ||||||||||
| New borrowing | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 8,550.70%12M |
| Refund | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -374.83%-18.86M | ---- | --6.86M |
| Interest paid - financing | 42.07%-84K | 41.77%-230K | ---145K | -55.51%-395K | ---- | -182.22%-254K | ---- | 59.28%-90K | ---- | -52.41%-221K |
| Dividends paid - financing | ---- | 66.67%-20M | ---- | ---60M | ---- | ---- | ---- | ---- | ---- | ---40M |
| Other items of the financing business | --33.51M | ---- | ---- | ---- | -2,483.20%-63.65M | ---- | 87.45%-2.46M | ---- | 36.49%-19.63M | ---- |
| Net cash from financing operations | 1,094.40%31.95M | 61.85%-25M | 94.95%-3.21M | -1,138.00%-65.52M | -2,483.20%-63.65M | 78.44%-5.29M | 87.45%-2.46M | 6.18%-24.55M | 36.49%-19.63M | -760.91%-26.16M |
| Net Cash | -186.90%-9.38M | 33.75%-20.87M | 90.81%-3.27M | -190.92%-31.51M | -176.61%-35.56M | 32.08%34.65M | 441.04%46.42M | 139.87%26.24M | 66.74%-13.61M | -553.90%-65.81M |
| Begining period cash | -31.83%44.7M | -32.45%65.58M | -32.45%65.58M | 55.51%97.08M | 55.51%97.08M | 72.49%62.43M | 72.49%62.43M | -64.52%36.19M | -64.52%36.19M | 16.57%102M |
| Cash at the end | -43.30%35.33M | -31.83%44.7M | 1.28%62.31M | -32.45%65.58M | -43.48%61.52M | 55.51%97.08M | 382.06%108.85M | 72.49%62.43M | -63.03%22.58M | -64.52%36.19M |
| Cash balance analysis | ||||||||||
| Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | National Health Accounting Firm Co., Ltd. | -- | National Health Accounting Firm Co., Ltd. | -- | National Health Accounting Firm Co., Ltd. | -- | National Health Accounting Firm Co., Ltd. | -- | National Health Accounting Firm Co., Ltd. |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.